[Asia Economy Reporter Yoo Hyun-seok] IADI and Etron are showing strong performance. It appears that the news of the Sputnik V COVID-19 vaccine, jointly developed and produced by the Russian sovereign wealth fund (RDIF) and GL Rapha, surpassing 1 million vaccinations has had an impact.
As of 2:03 PM on the 6th, IADI was trading at 332 KRW, up 5.40% (17 KRW) compared to the previous trading day. Etron also rose by 1.93%.
The general vaccinations of the Sputnik V COVID-19 vaccine, jointly developed and produced by the Russian sovereign wealth fund (RDIF) and GL Rapha, have exceeded 1 million people. Russia began full-scale vaccinations with 'Sputnik V,' developed by the Gamaleya Institute under the Ministry of Health, in early December last year. It is expected that a total of 1.5 million doses of the vaccine will be supplied across Russia by the end of this week.
Meanwhile, RDIF announced on its website that 260 doses of the Sputnik V vaccine will be supplied to Bolivia. The vaccine supply for Bolivia is sufficient to vaccinate more than 20% of the Bolivian population and will be supplied through RDIF’s international partners, including Korea Corus, the vaccine contract manufacturer, as well as partners in India and China.
Sputnik V, known to have an efficacy rate of over 90%, is an adenovirus-based vaccine similar to the AstraZeneca vaccine. The cost per dose is under 10 USD, and it is a freeze-dried vaccine stored at temperatures between 2 to 8 degrees Celsius, making it easy to supply to the global market.
IADI and Etron made an equity investment worth 20 billion KRW in Korea Corus last month.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
